Orchid Pharma Limited (ORCHPHARMA) reports strong Q2 FY27 results with a 148% surge in EBITDA, highlighting the success of its 'Soil to VialFROM' initiative.
Orchid Pharma Limited (ORCHPHARMA) expands Exblifep into Latin America through a licensing deal with Libra, targeting serious hospital infections.
Orchid Pharma Limited (ORCHPHARMA) signs licensing agreement with Pharmasyntez to commercialize Exblifep® in Russia, targeting USD 178 million over 10 years.